CHA Biotech Co. Ltd (085660) - Total Liabilities
Based on the latest financial reports, CHA Biotech Co. Ltd (085660) has total liabilities worth ₩1.83 Trillion KRW (≈ $1.24 Billion USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 085660 long-term investments to assets to see how much of total assets are deployed in long-term investments.
CHA Biotech Co. Ltd - Total Liabilities Trend (2008–2025)
This chart illustrates how CHA Biotech Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 085660 total asset value.
CHA Biotech Co. Ltd Competitors by Total Liabilities
The table below lists competitors of CHA Biotech Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Chongqing VDL Electronics Co. Ltd. A
SHE:301121
|
China | CN¥1.58 Billion |
|
NH SPAC 8
KQ:225570
|
Korea | ₩148.24 Billion |
|
Sprout Social Inc
NASDAQ:SPT
|
USA | $293.41 Million |
|
Shanghai Phoenix Enterprise Group Co Ltd A
SHG:600679
|
China | CN¥1.14 Billion |
|
Sijin Intelligent Forming Machinery
SHE:003025
|
China | CN¥296.09 Million |
|
Dymatic Chemicals Inc
SHE:002054
|
China | CN¥3.43 Billion |
|
Teck Resources Limited
F:TPT
|
Germany | €19.43 Billion |
|
Jiangsu Lianfa Textile Co Ltd
SHE:002394
|
China | CN¥1.24 Billion |
Liability Composition Analysis (2008–2025)
This chart breaks down CHA Biotech Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See CHA Biotech Co. Ltd (085660) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.89 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 4.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.64 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CHA Biotech Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CHA Biotech Co. Ltd (2008–2025)
The table below shows the annual total liabilities of CHA Biotech Co. Ltd from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩1.74 Trillion ≈ $1.18 Billion |
-8.97% |
| 2024-12-31 | ₩1.91 Trillion ≈ $1.29 Billion |
+78.60% |
| 2023-12-31 | ₩1.07 Trillion ≈ $724.61 Million |
-18.71% |
| 2022-12-31 | ₩1.32 Trillion ≈ $891.34 Million |
+21.89% |
| 2021-12-31 | ₩1.08 Trillion ≈ $731.27 Million |
+12.57% |
| 2020-12-31 | ₩958.62 Billion ≈ $649.64 Million |
+22.00% |
| 2019-12-31 | ₩785.74 Billion ≈ $532.48 Million |
+26.62% |
| 2018-12-31 | ₩620.54 Billion ≈ $420.53 Million |
+10.25% |
| 2017-12-31 | ₩562.87 Billion ≈ $381.45 Million |
+16.63% |
| 2016-12-31 | ₩482.61 Billion ≈ $327.06 Million |
+36.05% |
| 2015-12-31 | ₩354.73 Billion ≈ $240.39 Million |
+93.39% |
| 2014-12-31 | ₩183.43 Billion ≈ $124.31 Million |
+5.96% |
| 2013-12-31 | ₩173.12 Billion ≈ $117.32 Million |
-7.45% |
| 2012-12-31 | ₩187.06 Billion ≈ $126.76 Million |
-1.32% |
| 2011-12-31 | ₩189.56 Billion ≈ $128.46 Million |
+7.67% |
| 2010-12-31 | ₩176.06 Billion ≈ $119.32 Million |
+71.36% |
| 2009-12-31 | ₩102.75 Billion ≈ $69.63 Million |
+402.00% |
| 2008-12-31 | ₩20.47 Billion ≈ $13.87 Million |
-- |
About CHA Biotech Co. Ltd
Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising f… Read more